Abstract-The chemokine CXC receptor 4 (CXCR4) is activated by stromal cell-derived factor (SDF-1α). CXCR4 may be part of a lipopolysaccharide (LPS) sensing co-clustering complex that modulates TLR4 activation and evidence suggest that SDF-1α can activate anti-inflammatory signaling pathways and suppress inflammation. In the present study we examined the hypothesis that the SDF-1α peptide analog and CXCR4 agonist CTCE-0214 is anti-inflammatory in three distinct models of murine systemic inflammation. Our findings demonstrate that CTCE-0214 in vivo significantly suppressed plasma tumor necrosis factor alpha (TNF-α) increases in acute endotoxemia and following zymosan-induced multiple organ dysfunction syndrome (MODS). In both models, CTCE-0214 did not suppress plasma increases in the anti-inflammatory cytokine interleukin (IL)-10. CTCE-0214 improved survival without antibiotics in a model of severe sepsis induced by cecal ligation and puncture (CLP). CTCE-0214 also decreased plasma increases in IL-6 but not TNF-α and IL-10 in response to CLP-induced inflammation. We demonstrated in a moderately severe model of CLP (one puncture) that IL-6 levels at 24 h were similar to sham controls. However in severe CLP (two punctures) plasma IL-6 levels were markedly elevated. Plasma SDF-1α levels varied inversely with the plasma IL-6. In addition to the beneficial effect of CTCE-0214 in these models of systemic inflammation in vivo, we also demonstrated that the analog dose dependently suppressed LPS-induced IL-6 production in bone marrow-derived macrophages. CTCE-0214 therefore may be beneficial in controlling inflammation sepsis and systemic inflammatory syndromes.
INTRODUCTION
Pattern recognition receptors are fundamental to the innate immune response and in the pathophysiology of sepsis. It is well established that CD14 and MD-2 are cell surface receptor components necessary for TLR4 activation [1, 2] . Although the importance of the TLR4 sensing complex has been established, LPS sensing by other receptors is suggested by receptor clustering with TLR4 upon LPS stimulation [3, 4] . It has been demonstrated that CXCR4 is part of the LPS sensing co-clustering complex and that LPS can bind to CXCR4 resulting in the activation of signaling pathways [5] . Since CXCR4 activates heterotrimeric Gα i proteins, CXCR4 may be a TLR4 coclustering receptor that modulates Gα i activation in endotoxemia and sepsis. The natural ligand for CXCR4 is stromal cell-derived factor (SDF-1α) also referred to as CXCL12. SDF-1α is a multifunctional cytokine that is expressed and secreted by several tissues, including endothelium and stromal cells [6] . Recent studies suggest that SDF-1α activates both CXCR4 and CXCR7 [7] . During the inflammation process, SDF-1α is released at the site of injury. It has been demonstrated that SDF-1α reverses antigen-induced T cells recruitment into inflammatory sites [8] . Evidence suggests that SDF-1α can activate anti-inflammatory signaling pathways and suppress inflammation [8] [9] [10] . SDF-1α therefore may function as an autocrine or paracrine ligand that suppresses inflammation.
Our previous studies and others demonstrated that TLR4 signaling is, in part, Gα i protein-coupled [11] . Gα i2 (−/−) mice exhibit an enhanced pro-inflammatory phenotype to endotoxemia and CLP-induced sepsis compared with Gα i2 (+/+) mice [12] [13] [14] . Thus, the predominant function of Gα i signaling pathways in sepsis appears to be anti-inflammatory.
The function of SDF-1α can be mimicked by small peptide agonists [15] . CTCE-0214 is a peptide analog of SDF-1α, which has been modified to improve plasma stability [16] . In the present study we examined the efficacy of CTCE-0214 as a CXCR4 agonist in vivo on the inflammatory response to acute endotoxemia, in a MODS model induced by peritoneal zymosan, and on mortality induced by CLP in mice. Since SDF-1α is the endogenous ligand for CXCR4, we also measured plasma SDF-1α in CLP models with differing sepsis severity. Additionally in vitro effects of CTCE-0214 were examined in LPS-stimulated BMDM.
MATERIALS AND METHODS

CTCE-0214 Peptide
CTCE-0214 is a peptide analog of SDF-1α, which links the N-terminal region (residue, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , and the Cterminal region (residue, 55-67) of SDF-1α by a fourglycine linker. This analog is cyclized between amino acid residues at positions 20 and 24. Two Cys were replaced with Ala and Phe to improve plasma stability ( Fig. 1 ) (Chemokine Therapeutics Corporation).
Mice
Male CD-1 mice (7-8 weeks old) were purchased from Harlan laboratories. Investigations conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health and commenced with the approval of the Institutional Animal Care and Use Committee.
Cell Culture and Stimulation
Bone marrow-derived macrophages (BMDM) were isolated and cultured from CD-1 mice as previously described [17] . Briefly, mice were killed under anesthesia with ether, and both femurs were dissected free of adherent tissue. The proximal and distal femurs were removed and the marrow tissue was flushed by irrigation with culture medium. The marrow plugs were dispersed by passing through a 25-gauge needle, and the cells were suspended by vigorous pipetting and washed. Cells were cultured in DMEM containing 10% FBS, 50μg/ml penicillin/streptomycin and 25 ng/ml macrophage colony-stimulating factor (M-CSF; R&D system). Cells were incubated at 37°C in a humidified 5% CO 2 atm and fresh medium with M-CSF was added every 3 days. After 9 days of culture a homogeneous population of adherent macrophages was obtained (>90% F4/80+ cells as determined by flow cytometry, data not shown). BMDMs were incubated with CTCE-0214 (28-280 nM) for 1 h followed by stimulation with LPS (100 ng/ml, Sigma) for 18 h. The supernatants were collected for assay of interleukin (IL)-6 production.
LPS Shock
LPS shock was induced by intraperitoneal injection of LPS (25 mg/kg). CTCE-0214 (1 to 25 mg/kg) was administrated by i.v. injection at the same time as LPS administration. Dosing of CTCE-0214 was chosen based on previous publication [18] . PBS was used as vehicle control. One hour after LPS injection the mice were killed. Control mice received saline injections. Plasma tumor necrosis factor alpha (TNF-α), IL-6 and IL-10 levels were determined by enzyme-linked immunosorbant assay (ELISA).
Zymosan-Induced Peritonitis Model
We employed a zymosan model, a clinically relevant model of sterile peritonitis that induces multiple organ dysfunction [19] . Zymosan peritonitis was induced by injection (i.p.) of zymosan (500 mg/kg). CTCE-0214 (25 mg/kg) was administered (i.v. at 1 and 3 h and i.p. at 6 h) post zymosan injection. Control mice received saline injections. Twenty-four hours after zymosan challenge, mice were killed and plasma TNF-α, IL-6, and IL-10 were measured by ELISA (eBioscience, San Diego, CA).
Cecal Ligation and Puncture
Cecal ligation and puncture (CLP) was performed in CD-1 mice as previously described [17] . Specifically, mice were anesthetized with ether and a midline incision was made below the diaphragm to expose the cecum. The cecum was ligated at the colon juncture with a 5-0 silk ligature suture without interrupting intestinal continuity and punctured once or twice with a 22-gauge needle. The cecum was returned to the abdomen, and the incision was closed in layers with a 5-0 silk ligature suture and wound clips. After the procedure, the animals were fluid resuscitated with a 1.0-ml sterile saline injected subcutaneously. Sham operation was performed the same as CLP except for the ligation and puncture of the cecum.
For the survival study, CD-1 mice (n=15/group) were subjected to severe CLP (two-puncture model) or sham operation. CTCE-0214 (25 mg/kg) was administrated by injection subcutaneously at 2, 18, 26, 42, and 50 h after CLP. Survival was monitored every 12 h for a total of 120 h.
To determine plasma TNF-α, IL-6, and IL-10 production, CD-1 mice (three per group) were subjected to sham and another two groups were subjected to CLP (four to five per group). CTCE-0214 (10 mg/kg) was administrated by injection subcutaneously at 2 and 6 h after CLP. Mice were killed at 24 h after CLP. Plasma TNF-α, IL-6, and IL-10 production were determined by ELISA.
For measurement of plasma SDF-1α and IL-6 levels, CD-1 mice were subjected to the moderate sepsis model (CLP induced by one puncture with 22-guage needle, which results in more than 50% survival at 120 h (data not shown)) and severe sepsis model (CLP induced by two punctures with 22-guage needle, which results in less than 10% survival at 120 h (data not shown)). Twenty-four hours after CLP, mice were killed.
Assay for TNF-α, IL-6, IL-10, and SDF-1α Production TNF-α, IL-6 and IL-10 levels were measured using mouse TNF-α, IL-6 or IL-10 ELISA (eBioscience, San Diego, CA). Plasma SDF-1α levels also were determined by ELISA (R&D System).
Statistical Analysis
Data are expressed as the mean±standard error of the mean. Statistical significance was determined by analysis of variance with Fisher's probable least squares difference test or student t test using GraphPad Prism software. Logrank (Mantel-Cox) Test was used for survival studies. p< 0.05 was considered statistically significant. 
SDF-1 : KPVSLSYRCPCRFFESHVARANVKHLKILNTP NCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALN-OH
CTCE-0214: KPVSLSYRAPFRFF-linker-LKWIQEYLEKALN-OH
RESULTS
CTCE-0214 Suppresses LPS-Induced Plasma TNF-α Production
To test the potential beneficial effects of CTCE-0214, we determined its effect on LPS-induced shock. CTCE-0214 (1, 10, or 25 mg/kg) was administrated by i.v. injection at the same time as LPS administration. CTCE-0214 significantly decreased LPS-induced plasma TNF-α production in a dose dependent manor with a 93 ±4% reduction, p<0.05 (Fig. 2a) . CTCE-0214 has no significant effect on LPS-induced plasma IL-6 and IL-10 production (Fig. 2b, c) CTCE-0214 Decreased Zymosan-Induced Plasma TNF-α but Not IL-10 Production
To further test the efficacy of CTCE-0214, peritonitis was induced using zymosan, a clinically relevant model of sterile peritonitis that induces multiple organ dysfunction [19] . Zymosan peritonitis was induced by injection (i.p.) of zymosan (500 mg/kg). CTCE-0214 (25 mg/kg) was administered (i.v. at 1 and 3 h and i.p. at 6 h) post zymosan injection. We found a significant reduction in plasma TNF-α (53±10% reduction, p<0.05) but not in IL-6 and IL-10 production in CTCE-0214-treated group compared to vehicle (PBS) group (Figs. 3a-c) .
CTCE-0214 Suppresses Severe CLP-Induced Mortality
To determine the effect of CTCE-0214 in severe septic shock, severe sepsis was induced by CLP with two punctures with 22-gauge needle. This results in less than 10% survival at 120 h (Fig. 4a) . CTCE-0214 (25 mg/kg) was administrated by injection subcutaneously at 2, 18, 26, 42, and 50 h after CLP. CTCE-0214 significantly reduced mortality induced by CLP (p<0.05, Fig. 4a ). CTCE-0214 also significantly suppresses CLPinduced plasma IL-6 production but not TNF-α and IL-10 production compare to PBS group (Fig. 4b-d) .
SDF-1α Expression is Increased in Less Severe CLP but Inhibited in Severe CLP
Mice were subjected to moderate sepsis, using one puncture with a 22-gauge needle, which results in more than 50% survival at 120 h (data not shown). Twentyfour hours after CLP, mice were killed and plasma was collected. Since plasma IL-6 levels have been shown to be an indicator of sepsis severity and correlate with 3 . Effect of CTCE-0214 on zymosan-induced plasma TNF-α, IL-6, and IL-10 production. CD-1 mice were injected with zymosan (500 mg/kg, i.p.). One and three hours after zymosan injection, mice were injected with CTCE-0214 (25 mg/kg, i.v.). Six hours after zymosan injection, mice were injected with CTCE-0214 (25 mg/kg, i.p.). Twenty-four hours after zymosan challenge, mice were killed and plasma TNF-α (a), IL-6 (b), and IL-10 (c) were measured by ELISA. *p<0.05 compared with control; #p<0.05 compared with zymosan stimulation. N=3-6.
sepsis outcome [20] plasma IL-6 was measured in relationship to plasma SDF-1α. Plasma IL-6 levels were the same as sham in the moderate CLP model but markedly increased in the severe CLP (Fig. 5a ). SDF-1α levels were increased in the moderate CLP, but decreased back to sham levels in the severe CLP (Fig. 5b) .
CTCE-0214 Inhibited LPS-Induced IL-6 Production in BMDM
BMDMs were incubated with CTCE-0214 (28-280nM) for 1 h followed by stimulation with LPS (100 ng/ml) for 18 h. CTCE-0214 significantly decreased LPS-induced IL-6 production (Fig. 6) .
DISCUSSION
Our findings demonstrate that the SDF-1α analog and CXCR4 agonist CTCE-0214 is effective in vivo in suppressing plasma TNF-α in acute endotoxemia and zymosan-induced MODS. In both models CTCE-0214 did not suppress plasma increases in the anti-inflamma- tory cytokine IL-10. CTCE-0214 improved survival without antibiotics in a severe model of sepsis induced by CLP. CTCE-0214 also suppressed plasma increases in IL-6 but not TNF-α and IL-10 in response to CLP. Plasma IL-6 has been shown to be a predictor of sepsis severity [20] . We demonstrated in a moderately severe model of CLP (one puncture) that IL-6 levels at 24 h were similar to sham controls. However in severe CLP (two punctures) plasma IL-6 levels were markedly elevated. Interestingly plasma SDF-1α levels varied inversely with the plasma IL-6. Studies have demonstrated that inflammatory cytokines suppress SDF-1α production and CXCR4 expression [21] . In addition to the beneficial effect of CTCE-0214 in these models of systemic inflammation, we also demonstrated that the analog suppressed LPS-induced IL-6 production in BMDM.
To the best of our knowledge these results are the first to demonstrate in vivo beneficial effects of an SDF-1α analog in these murine models of severe inflammation. The mechanisms whereby CTCE-0214 mediates an antiinflammatory effect remain unclear. SDF-1α has been shown to have multifunctional effects on varied cell types. In T cells SDF-1α has been shown to suppress antigeninduced recruitment to inflammatory sites [8] . SDF-1α suppresses LPS-stimulated tissue factor, and decreases phytohemagglutinin-induced inflammatory mediator MCP-1, IL-8, and matrix metalloproteinase-9 production in peripheral blood mononuclear cells from angina patients [9] . SDF-1α is protective in ischemia/reperfusion injury [10] . In that study infusion of SDF-1α prior to murine coronary artery occlusion followed by 4 h of reperfusion was accompanied by a reduction in infarct size. A CXCR4 antagonist abrogated this protection. In isolated myocytes, SDF-1α induced ERK1/2 and AKT activation but suppressed JNK and p38 phosphorylation. The authors concluded that SDF-1α and its receptor might afford protection from hypoxic stimuli by recruiting anti-apoptotic kinases ERK and AKT. In sepsis the PI3K-AKT pathway negatively regulates inflammatory processes and inhibition of PI3K-AKT signaling increases susceptibility to polymicrobial sepsis [22] . Thus, SDF-1α and its cognate chemokine receptor may play a key role in modulating the PI3K-AKT anti-apoptotic and anti-inflammatory pathways in sepsis. In addition to these signaling pathways hemoxygenase-1 (HO-1) appears to be important in hypoxic stress and mice deficient in HO-1 are more susceptible to polymicrobial sepsis [23] . Both vascular endothelial growth factor (VEGF) and SDF-1α may mediate transfected HO-1 protection in mice with ischemic infarction [24] . HO-1 transfection of cardiomyocytes induces VEGF and SDF-1α expression whereas neutralizing antibodies to VEGF and SDF-1α abrogated the protective effect of HO-1 in ischemic injury. . Effect of CTCE-0214 on LPS-induced IL-6 production in B-MDM. BMDMs from CD-1 mice were incubated with CTCE-0214 (28-280nM) for 1 h followed by activation with LPS (100 ng/ml, Sigma) for 18 h. LPS-induced IL-6 production was examined by ELISA. *p<0.05 compared with basal control; #p<0.05 compared with LPS stimulation. N=3.
Pattern recognition receptors and proximal signaling events could also be altered by CTCE-0214. CXCR4 has been implicated as a sensing apparatus for LPS in addition to the TLR4, MD2, CD14 complex which forms a coclustering complex of CXCR4 and TLR4 in lipid rafts upon LPS stimulation [3, 5] . Since LPS may directly activate CXCR4, CTCE-0214 could antagonize LPS binding. Activation of CXCR4 by SDF-1α in transfected HEK cells has been shown to suppress nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation in response to LPS stimulation whereas receptor antagonism of CXCR4 enhanced LPS-induced NF-κB activation. Thus the reduced TNF-α production in vivo observed with CTCE-0214 in acute endotoxemia may in part be a consequence of receptor antagonism or inhibition of NF-κB activation. However, zymosan-induced MODS and polymicrobial sepsis involve multiple TLRs and other protein recognition receptors in addition to TLR4. Also, SDF-1α binds to CXCR7. It is possible that CTCE-0214 binds to CXCR7 and regulates the LPS response. However, this possibility remains to be furhter investigated. Since CXCR4 is a Gα i protein coupled receptor, activation of Gα i signaling pathways may regulate TLR activation [12] [13] [14] . Of key relevance to the present findings is our previous observation that Gα i2 (−/−) mice exhibit a profound pro-inflammatory phenotype to endotoxemia and CLP-induced sepsis [12, 25] . It is speculated that genetic deletion of Gα i removes the protective function of CXCR4 in MODS and sepsis. Thus activation of CXCR4 by autocrine or paracrine mechanisms may constitute a negative feedback pathway to control the systemic inflammatory response in critical illness. The present studies demonstrate that CTCE-0124 is beneficial in three distinctly different models of murine inflammation.
